

Funded antiretrovirals

Information taken from [www.pharmac.govt.nz/wwrts/HMLOnline](http://www.pharmac.govt.nz/wwrts/HMLOnline) on 15 Oct 19

| <b>Drug</b>                                | <b>Monthly cost (at normal adult dose)</b> |
|--|--|
| Efavirenz with emtricitabine and tenofovir | \$107                                      |
| Emtricitabine with tenofovir               | \$61                                       |
| Emtricitabine                              | \$307                                      |
| Efavirenz                                  | \$63                                       |
| Nevirapine                                 | \$60                                       |
| Abacavir with lamivudine                   | \$63                                       |
| Zidovudine with lamivudine                 | \$33                                       |
| Atazanavir (plus ritonavir)                | \$185                                      |
| Lopinavir with ritonavir                   | \$463                                      |
| Darunavir (plus ritonavir)                 | \$378                                      |
| Dolutegravir†                              | \$1090                                     |
| Raltegravir†                               | \$1090                                     |

| <b>Commonly used starting regimens</b>         | <b>Yearly cost</b> |
|--|--------------------|
| Efavirenz with emtricitabine and tenofovir     | \$1,284            |
| Emtricitabine with tenofovir and dolutegravir† | \$13,812           |
| Emtricitabine with tenofovir and darunavir/r   | \$5,268            |

†Subject to a confidential pricing rebate (i.e. PHARMAC nationally agreed contract price is cheaper but secret)

RELEASED UNDER THE  
OFFICIAL INFORMATION ACT